References
- Committee for Proprietary Medicinal Products (CPMP).. Points to consider on missing data: the European Agency for the Evaluation of Medicinal Products (EMEA). 2001
- De Deyn PP, D'Hooge R. Placebos in clinical practice and research. J Med Ethics 1996; 22:140–6
- Fisher LD, Dixon DO, Herson J, . Intention-to-treat in clinical trials. Statistical issues in drug research and developmentPeace KE. New York: Raven Press, 1990
- Frangakis CE, Rubin DB. Addressing the complications of intention-to-treat analysis in the combined presence of all-or-none treatment non-compliance and subsequent missing outcomes. Biometrika 1999; 86:365–79
- ICH Topic E9: statistical principles for clinical trials. Note for guidance on statistical principles for clinical trials: the European Agency for the Evaluation of Medicinal Products (EMEA). 1998
- Altman DG, Schulz KF, Moher D, . The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134:663–94
- Mazumdar S, Liu KS, Houck PR, . Intent-to-treat analysis for longitudinal clinical trials: coping with the challenge of missing values. J Psychiatr Res 1999; 33:87–95
- Little RJA, Rubin DB. Statistical analysis with missing data, 2nd ed. Chichester: Wiley, 2002
- Youk AO, Stone RA, Marsh GM. A method for imputing missing data in longitudinal studies. Ann Epidemiol 2004; 14:354–61
- Mallinckrodt CH, Clark SW, Carroll RJ, . Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat 2003; 13:179–90
- Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. Br Med J 1999; 319:670–4
- Moyle GJ. Truth, lies, and statistical tests. AIDS Read 2003; 13:117–8. 123-4, 126
- Wright CC, Sim J. Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis. J Clin Epidemiol 2003; 56:833–42
- Rubin DB. Inference and missing data. Biometrika 1976; 63:581–92
- Gottlieb AB, Hamilton T, Caro I, . Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006; 54 (Suppl 1) S154–S163
- Hill A, Demasi R. Discordant conclusions from HIV clinical trials – an evaluation of efficacy endpoints. Antiviral Ther 2005; 10:367–74
- Aidsmap forum reports.. How to interpret research studies. 2004. [cited February 27, 2006]; Available from: http://www.aidsmap.com/en/docs/02F26BC6-6841-4612-8647-79D0C10DD043.asp